Trial Outcomes & Findings for Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron (NCT NCT01950247)

NCT ID: NCT01950247

Last Updated: 2025-05-22

Results Overview

The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

1025 participants

Primary outcome timeframe

Baseline to Day 30

Results posted on

2025-05-22

Participant Flow

Participant milestones

Participant milestones
Measure
IV Iron Standard of Care (SOC)
At a dose and administration regimen as determined by the study site investigator Standard of Care (SOC)
Injectafer
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Overall Study
STARTED
512
513
Overall Study
COMPLETED
455
467
Overall Study
NOT COMPLETED
57
46

Reasons for withdrawal

Reasons for withdrawal
Measure
IV Iron Standard of Care (SOC)
At a dose and administration regimen as determined by the study site investigator Standard of Care (SOC)
Injectafer
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Overall Study
Withdrawal by Subject
28
13
Overall Study
Lost to Follow-up
18
16
Overall Study
Physician Decision
3
4
Overall Study
Adverse Event
3
2
Overall Study
Death
1
1
Overall Study
Not Defined
4
10

Baseline Characteristics

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator SOC
Total
n=1025 Participants
Total of all reporting groups
Age, Continuous
57.2 years
STANDARD_DEVIATION 16.58 • n=99 Participants
55.7 years
STANDARD_DEVIATION 16.68 • n=107 Participants
56.5 years
STANDARD_DEVIATION 16.64 • n=206 Participants
Sex: Female, Male
Female
421 Participants
n=99 Participants
409 Participants
n=107 Participants
830 Participants
n=206 Participants
Sex: Female, Male
Male
92 Participants
n=99 Participants
103 Participants
n=107 Participants
195 Participants
n=206 Participants
Region of Enrollment
United States
513 Participants
n=99 Participants
512 Participants
n=107 Participants
1025 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline to Day 30

Population: Change from baseline to Day 30

The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.

Outcome measures

Outcome measures
Measure
Injectafer
n=264 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=269 Participants
At a dose and administration regimen as determined by the study site investigator SOC
Multidimensional Assessment of Fatigue (MAF) Scores
-8.8 units on a scale
Standard Deviation 11.38
-8.1 units on a scale
Standard Deviation 11.28

PRIMARY outcome

Timeframe: Baseline and Day 30

Population: Change from baseline to Day 30

The WPAI consisted of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working using a scale of 0 to 10, with 0 = PROBLEM had no effect on my work and 10 = PROBLEM completely prevented me from working; 6 = degree health affected productivity in regular unpaid activities using a scale of 0 to 10, with 0 = PROBLEM had no effect on my daily activities and 10 = PROBLEM completely prevented me from doing my daily activities. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator SOC
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent activity impairment due to problem
-15.2 units on a scale
Standard Deviation 29.85
-11.5 units on a scale
Standard Deviation 29.43
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent impairment while working due to problem
-13.2 units on a scale
Standard Deviation 28.75
-8.5 units on a scale
Standard Deviation 24.44
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent overall work impairment due to problem
-13.4 units on a scale
Standard Deviation 31.66
-8.5 units on a scale
Standard Deviation 25.89
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent work time missed due to problem
-3.2 units on a scale
Standard Deviation 23.76
-2.5 units on a scale
Standard Deviation 17.23

PRIMARY outcome

Timeframe: Baseline and Day 30

Population: Change from baseline to Day 30

Participants rated 14 items with 4 domains. Scores for item 1 to 3, 9 to 11 and 14 ranged from 1=extremely dissatisfied to 7=extremely satisfied. Items 5 to 8, 12, 13 ranged from 1=extremely dissatisfied to 5=not at all dissatisfied. Item 4 was scored as: 0=No, 1=Yes. Effectiveness measured as (\[{sum of item 1 to 3} - 3\]/18)\*100; if 1 question (Q) was missing: (\[{sum of item 1 to 3} -2\]/12)\*100. Side-effect measured as if item 4=No, score=100; if not then (\[{sum of item 5 to 8} -4\]/16)\*100; if 1 Q was missing: (\[{sum of item 5 to 8} -3\]/12)\*100. Convenience measured as (\[{sum of item 9 to 11} -3\]/18)\*100; if 1 Q was missing: (\[{sum of item 9 to 11} - 2\]/12)\*100. Global satisfaction as (\[{sum of item 12 to 14} -3\]/14)\*100; if item 12 or 13 was missing: (\[{sum of item 12 to 14} -2\]/10)\*100; if item 14 was missing: (\[{sum of item 12 and 13} -2\]/8)\*100. All domains had scale of 0 (no satisfaction) to 100 (best level of satisfaction), higher score equals greater satisfaction

Outcome measures

Outcome measures
Measure
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator SOC
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Overall Satisfaction
72.6 units on a scale
Standard Deviation 25.03
72.7 units on a scale
Standard Deviation 21.07
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Effectiveness
69.3 units on a scale
Standard Deviation 22.38
66.5 units on a scale
Standard Deviation 21.75
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Side Effects
63.5 units on a scale
Standard Deviation 27.21
69.2 units on a scale
Standard Deviation 21.00
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Convenience
78.9 units on a scale
Standard Deviation 17.31
72.8 units on a scale
Standard Deviation 20.00

PRIMARY outcome

Timeframe: Baseline and Day 30

Population: Change from Baseline to Day 30

The SF-12 is a multipurpose short form to measure health status. There are 10 domains: Physical Composite Index (score range from 0-100); Physical Functioning Index (score range from 0-100); Role Limitation Physical Index (score range 0-100); Pain Index Score (score range from 0-100); General Health Index (score range from 0-100); Mental Health Composite Index (score range from 1-100); Vitality Index (score range from 0-100); Social Functioning Index (score rang 0-100); Role Limitation Emotional Index (score range 0-100); and SF-12 Mental Health Index (score range from 0-100), the higher the score means a better outcome. The overall scale and sub-scales were calculated with the standard SF-12 formulas.

Outcome measures

Outcome measures
Measure
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator SOC
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Role Limitation Physical
4.0 units on a scale
Standard Deviation 9.53
3.9 units on a scale
Standard Deviation 9.25
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Vitality
7.7 units on a scale
Standard Deviation 11.36
7.0 units on a scale
Standard Deviation 11.53
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Pain
1.6 units on a scale
Standard Deviation 10.03
2.5 units on a scale
Standard Deviation 10.52
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Overall Physical Health Score
3.3 units on a scale
Standard Deviation 7.94
3.1 units on a scale
Standard Deviation 8.33
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Overall Mental Health Score
3.7 units on a scale
Standard Deviation 10.31
3.7 units on a scale
Standard Deviation 10.39
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Physical Functioning
3.6 units on a scale
Standard Deviation 10.42
3.4 units on a scale
Standard Deviation 10.45
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
General Health
3.2 units on a scale
Standard Deviation 9.86
2.5 units on a scale
Standard Deviation 9.84
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Social Functioning
3.6 units on a scale
Standard Deviation 12.19
3.0 units on a scale
Standard Deviation 11.47
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Role Limitation Emotion
2.7 units on a scale
Standard Deviation 12.69
2.8 units on a scale
Standard Deviation 12.62
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Mental Health
2.9 units on a scale
Standard Deviation 10.10
3.3 units on a scale
Standard Deviation 9.62

Adverse Events

Injectafer

Serious events: 4 serious events
Other events: 28 other events
Deaths: 1 deaths

IV Iron Standard of Care (SOC)

Serious events: 1 serious events
Other events: 21 other events
Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure
Injectafer
n=513 participants at risk
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 participants at risk
At a dose and administration regimen as determined by the study site investigator SOC
Cardiac disorders
Cardiac disorders
0.78%
4/513 • Number of events 506 • Day 1 to Day 30
Adverse events were collected by systematic assessment
0.20%
1/512 • Number of events 486 • Day 1 to Day 30
Adverse events were collected by systematic assessment

Other adverse events

Other adverse events
Measure
Injectafer
n=513 participants at risk
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg. Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
IV Iron Standard of Care (SOC)
n=512 participants at risk
At a dose and administration regimen as determined by the study site investigator SOC
Gastrointestinal disorders
Nausea
5.5%
28/513 • Number of events 506 • Day 1 to Day 30
Adverse events were collected by systematic assessment
4.1%
21/512 • Number of events 486 • Day 1 to Day 30
Adverse events were collected by systematic assessment

Additional Information

Mark Falone, MD.

American Regent, Inc.

Phone: 631.772.3544

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place